ES2395890T3 - Ensayo de diagnóstico, predictivo y de prognosis para el cáncer - Google Patents

Ensayo de diagnóstico, predictivo y de prognosis para el cáncer Download PDF

Info

Publication number
ES2395890T3
ES2395890T3 ES08840139T ES08840139T ES2395890T3 ES 2395890 T3 ES2395890 T3 ES 2395890T3 ES 08840139 T ES08840139 T ES 08840139T ES 08840139 T ES08840139 T ES 08840139T ES 2395890 T3 ES2395890 T3 ES 2395890T3
Authority
ES
Spain
Prior art keywords
biomarker
level
cancer
predetermined value
aurora
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08840139T
Other languages
English (en)
Spanish (es)
Inventor
Kai Stoeber
Gareth Hayden Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Cancer Diagnostics Ltd
Original Assignee
Cambridge Cancer Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Cancer Diagnostics Ltd filed Critical Cambridge Cancer Diagnostics Ltd
Application granted granted Critical
Publication of ES2395890T3 publication Critical patent/ES2395890T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES08840139T 2007-10-15 2008-10-15 Ensayo de diagnóstico, predictivo y de prognosis para el cáncer Active ES2395890T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0720113 2007-10-15
GBGB0720113.0A GB0720113D0 (en) 2007-10-15 2007-10-15 Diagnostic, prognostic and predictive testing for cancer
PCT/GB2008/003501 WO2009050461A1 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer

Publications (1)

Publication Number Publication Date
ES2395890T3 true ES2395890T3 (es) 2013-02-15

Family

ID=38813827

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08840139T Active ES2395890T3 (es) 2007-10-15 2008-10-15 Ensayo de diagnóstico, predictivo y de prognosis para el cáncer

Country Status (11)

Country Link
US (3) US8512716B2 (enExample)
EP (1) EP2208070B1 (enExample)
JP (2) JP5559056B2 (enExample)
CN (1) CN101896819A (enExample)
AU (1) AU2008313459B2 (enExample)
CA (1) CA2702653A1 (enExample)
DK (1) DK2208070T3 (enExample)
ES (1) ES2395890T3 (enExample)
GB (1) GB0720113D0 (enExample)
PT (1) PT2208070E (enExample)
WO (1) WO2009050461A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921873D0 (en) 2009-12-15 2010-01-27 Cytosystems Ltd Assay
SG10201505723UA (en) * 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
WO2014179959A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Method and system for assessing health condition
CN103592444A (zh) * 2013-11-27 2014-02-19 中国人民解放军沈阳军区总医院 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法
US9857354B2 (en) 2014-06-01 2018-01-02 Novazoi Theranostics, Inc. Compositions and methods for prognosis and treatment of neoplasm
WO2016131875A1 (en) * 2015-02-17 2016-08-25 Biontech Diagnostics Gmbh Methods and kits for the molecular subtyping of bladder cancer
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
EP3304082B1 (en) 2015-06-08 2020-05-13 Arquer Diagnostics Limited Methods for analysing a urine sample
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
CN108344867B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人卵母细胞成熟分期中的应用
CN108344868B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人早期胚胎的发育分期中的应用
CN111187833A (zh) * 2018-11-14 2020-05-22 上海生物芯片有限公司 Plk1和bub1b基因联合作为肺癌生物标志物的用途
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method
CN109988708B (zh) * 2019-02-01 2022-12-09 碳逻辑生物科技(中山)有限公司 一种用于对患有结肠直肠癌的患者进行分型的系统
CN110846413B (zh) * 2019-11-23 2023-05-26 中南大学湘雅三医院 Mafg/mafg-as1/mafg正反馈环作为靶位点检测试剂的应用
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
JP2025507447A (ja) * 2022-02-01 2025-03-18 ４ディー・パス・インコーポレイテッド 画像に基づく疾患特性評価のためのシステム及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2563168A1 (en) * 2004-04-14 2005-11-17 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
JP2008530575A (ja) * 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ Ｃｈｋ１阻害薬に対する応答性を判定する方法
JP5474354B2 (ja) * 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
AU2006332806B2 (en) * 2005-12-30 2012-03-15 Ventana Medical Systems, Inc. Na+, K+-ATPase expression in cervical dysplasia and cancer

Also Published As

Publication number Publication date
JP2014095726A (ja) 2014-05-22
JP2011501809A (ja) 2011-01-13
WO2009050461A1 (en) 2009-04-23
GB0720113D0 (en) 2007-11-28
EP2208070A1 (en) 2010-07-21
US20140154680A1 (en) 2014-06-05
US20100285474A1 (en) 2010-11-11
JP5837630B2 (ja) 2015-12-24
JP5559056B2 (ja) 2014-07-23
US8512716B2 (en) 2013-08-20
AU2008313459A1 (en) 2009-04-23
US20180223366A1 (en) 2018-08-09
CN101896819A (zh) 2010-11-24
PT2208070E (pt) 2013-01-08
EP2208070B1 (en) 2012-10-03
AU2008313459B2 (en) 2013-01-24
DK2208070T3 (da) 2012-12-17
CA2702653A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
US8512716B2 (en) Diagnostic, predictive and prognostic testing for cancer
Garcia-Marcos et al. Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer
Roque et al. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones
Li et al. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
AU2010236415A1 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
US20120245051A1 (en) Objective, quantitative method to predict histological subtype in non-small cell lung cancer
Gruessner et al. Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma
Valentini et al. Claudin 18.2: An attractive marker in pancreatic ductal adenocarcinoma
Harb et al. PYCR1, BANF1, and STARD8 expression in gastric carcinoma: a clinicopathologic, prognostic, and immunohistochemical study
Zheng et al. RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma
KR20240156639A (ko) 암 진단 및 prmt5 억제제에 의한 치료
JPWO2004076686A1 (ja) 細胞の検査方法
Wang et al. Excision repair cross-complementing group 2 upregulation is a potential predictive biomarker for oral squamous cell carcinoma recurrence
Pérez-Morales et al. Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker
Li et al. RETRACTED ARTICLE: Octamer transcription factor 1 mediates epithelial-mesenchymal transition in colorectal cancer
Yu et al. NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes
Fang et al. Caspase-14 is an anti-apoptotic protein targeting apoptosis-inducing factor in lung adenocarcinomas
Ghorbani Ranjbary et al. Impacts of some clinicopathodemography and colorectal tissues key cell cycle and mucin stabilizing molecules on the metastasis trend in colorectal cancer patients
Cirello et al. FAM83B is involved in thyroid cancer cell differentiation and migration
JP2021508835A (ja) 腫瘍細胞中のＲＡＤ５１ ｆｏｃｉの検出に基づく方法
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
US20140200155A1 (en) Prognostic marker for endometrial carcinoma
Haddad et al. Epidermal growth factor receptor (EGFR) in the era of Precision Medicine: The tale of a perfect example of targeted therapy. A review
Sun et al. Loss of PRKACB facilitates metastasis of diffuse-type gastric cancer through RhoA signaling activation
Zanjirband The genomic and functional status of TP53 in ovarian cancer: biomarker for chemotherapy outcome and determinant of response to MDM2 inhibitors